Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on clinical developments of HER2-low breast cancer, including the Phase III DESTINY-Breast04 (NCT03734029) trial which was positive for the treatment of patients with HER2-low metastatic breast cancer with trastuzumab deruxtecan, by which an improved progression-free survival (PFS) and overall-survival (OS) was observed. An active area of investigation is defining HER2-low expression, due to the lack of concordance between pathologists. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.
